Auvality is NOT beneficial for Parkinson's disease patients
Auvality (maropitant) is a veterinary antiemetic medication approved exclusively for dogs and cats to prevent vomiting—it has no established role, approval, or evidence for use in Parkinson's disease or any human condition. 1
Critical Clarification
The evidence provided shows that Auvality (CERENIA Injectable Solution/Tablets) is an FDA-approved veterinary drug containing maropitant, an NK1 receptor antagonist used to:
- Prevent acute vomiting in dogs and cats
- Treat vomiting associated with chemotherapy (cisplatin) in dogs
- Manage motion sickness in dogs
Why This Matters for Parkinson's Disease
There is zero evidence supporting Auvality use in humans with Parkinson's disease. The provided guidelines extensively cover nutritional management, dysphagia screening, vitamin supplementation (particularly vitamin D, B12, and folate), and medical nutrition therapy for PD patients 2, but none mention maropitant or any veterinary antiemetic as a treatment option.
What PD Patients Actually Need:
For nausea/vomiting in PD patients, the evidence-based approach includes:
- Levodopa timing optimization: Take medications 30 minutes before meals to minimize gastrointestinal side effects 2
- Protein redistribution diets: For patients with motor fluctuations, redistribute protein intake (low-protein breakfast/lunch, normal protein at dinner) to improve levodopa absorption 2
- Nutritional monitoring: Regular assessment of body weight, vitamin D, folate, and B12 status 2
- Dysphagia screening: For Hoehn & Yahr stage >II or those with weight loss, low BMI, drooling, or dementia 2
Common Pitfall to Avoid
Do not confuse veterinary medications with human therapeutics. Maropitant has not undergone human safety or efficacy trials for any indication, including PD-related symptoms. Using veterinary drugs in humans poses serious safety risks including unknown adverse effects, inappropriate dosing, and lack of quality control for human use.
The Actual Evidence Base for PD Management
The guidelines emphasize 2:
- Vitamin D supplementation may slow disease progression and reduce fracture risk
- B12 and folate supplementation to prevent levodopa-induced hyperhomocysteinemia and neuropathy
- Medical nutrition therapy tailored to individual requirements improves quality of life
- Rehabilitation for dysphagia with individualized bolus modifications and postural maneuvers
If a PD patient experiences nausea or vomiting, appropriate human antiemetics should be prescribed by their physician, not veterinary medications.